Crucell Q4 disappoints analysts

Biotechnology company Crucell disheartened analysts across the board on Tuesday with disappointing Q4 figures. Crucell posted a loss of €24.9m in the last three months of 2006. The company had been forced to take a €33.5m provision for write-offs and a reorganisation.

Over the full year, Crucell’s loss totalled €87.6m, compared with a loss of €15.6m in 2005. Sales rose from €37.6m to €140.9m following the takeover of Swiss vaccination maker Berna Biotech.

Thank you for donating to

We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.

Make a donation